Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.

The following safety variables showed a trend for possible exposure–response relationship based on the quartile plots ( Figure 3 ) and were assessed further through logistic regression exposure–response models: > 2 g/dL decrease in hemoglobin from baseline at Week 12/14 and Week 24/26, lymphopenia Grade 3 or higher at Week 12/14, serious infections at Week 24/26.

also in 53,322 other papers